Zurich Cantonal Bank’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $452K | Hold |
47,980
| – | – | ﹤0.01% | 1999 |
|
|
2026
Q1 | $391K | Buy |
+47,980
| New | +$435K | ﹤0.01% | 1953 |
|
|
2025
Q4 | – | Sell |
-107,589
| Closed | -$811K | – | 3187 |
|
|
2025
Q3 | $933K | Buy |
107,589
+13,371
| +14% | +$104K | ﹤0.01% | 1331 |
|
|
2025
Q2 | $594K | Hold |
94,218
| – | – | ﹤0.01% | 1555 |
|
|
2025
Q1 | $604K | Hold |
94,218
| – | – | ﹤0.01% | 1486 |
|
|
2024
Q4 | $758K | Buy |
94,218
+5,292
| +6% | +$51K | ﹤0.01% | 1374 |
|
|
2024
Q3 | $1.12M | Hold |
88,926
| – | – | ﹤0.01% | 1070 |
|
|
2024
Q2 | $1.13M | Sell |
88,926
-4,287
| -5% | -$43.1K | ﹤0.01% | 1017 |
|
|
2024
Q1 | $446K | Buy |
93,213
+5,474
| +6% | +$25.4K | ﹤0.01% | 1545 |
|
|
2023
Q4 | $421K | Buy |
87,739
+27,436
| +45% | +$168K | ﹤0.01% | 1617 |
|
|
2023
Q3 | $437K | Buy |
60,303
+45,574
| +309% | +$364K | ﹤0.01% | 1483 |
|
|
2023
Q2 | $109K | Buy |
14,729
+1,948
| +15% | +$15.3K | ﹤0.01% | 2311 |
|
|
2023
Q1 | $88.6K | Buy |
12,781
+43
| +0.3% | +$396 | ﹤0.01% | 2351 |
|
|
2022
Q4 | $131K | Sell |
12,738
-1,570
| -11% | -$27.7K | ﹤0.01% | 2098 |
|
|
2022
Q3 | $260K | Sell |
14,308
-10,521
| -42% | -$456K | ﹤0.01% | 1595 |
|
|
2022
Q2 | $1.28M | Sell |
24,829
-30,390
| -55% | -$1.57M | 0.01% | 779 |
|
|
2022
Q1 | $4.07M | Buy |
55,219
+30,109
| +120% | +$2.68M | 0.02% | 555 |
|
|
2021
Q4 | $3.59M | Buy |
25,110
+3,575
| +17% | +$614K | 0.02% | 605 |
|
|
2021
Q3 | $4.46M | Buy |
21,535
+1,757
| +9% | +$387K | 0.02% | 549 |
|
|
2021
Q2 | $4.2M | Buy |
19,778
+12,108
| +158% | +$2.22M | 0.02% | 533 |
|
|
2021
Q1 | $1.39M | Sell |
7,670
-1,232
| -14% | -$246K | 0.01% | 789 |
|
|
2020
Q4 | $993K | Buy |
8,902
+2,368
| +36% | +$252K | 0.01% | 959 |
|
|
2020
Q3 | $708K | Buy |
6,534
+940
| +17% | +$115K | 0.01% | 943 |
|
|
2020
Q2 | $466K | Buy |
+5,594
| New | +$214K | ﹤0.01% | 1041 |
|
|
2019
Q4 | – | Sell |
-1,394
| Closed | -$7K | – | 2613 |
|
|
2019
Q3 | $7K | Hold |
1,394
| – | – | ﹤0.01% | 2583 |
|
|
2019
Q2 | $8K | Hold |
1,394
| – | – | ﹤0.01% | 2580 |
|
|
2019
Q1 | $15K | Buy |
1,394
+558
| +67% | +$17.6K | ﹤0.01% | 2475 |
|
|
2018
Q4 | $31K | Buy |
836
+475
| +132% | +$18.4K | ﹤0.01% | 2285 |
|
|
2018
Q3 | $14K | Hold |
361
| – | – | ﹤0.01% | 2523 |
|
|
2018
Q2 | $10K | Hold |
361
| – | – | ﹤0.01% | 2490 |
|
|
2018
Q1 | $15K | Hold |
361
| – | – | ﹤0.01% | 2453 |
|
|
2017
Q4 | $9K | Hold |
361
| – | – | ﹤0.01% | 2503 |
|
|
2017
Q3 | $8K | Hold |
361
| – | – | ﹤0.01% | 2453 |
|
|
2017
Q2 | $8K | Hold |
361
| – | – | ﹤0.01% | 2462 |
|
|
2017
Q1 | $9K | Hold |
361
| – | – | ﹤0.01% | 2491 |
|
|
2016
Q4 | $9K | Hold |
361
| – | – | ﹤0.01% | 2472 |
|
|
2016
Q3 | $15K | Buy |
361
+57
| +19% | +$7.36K | ﹤0.01% | 2323 |
|
|
2016
Q2 | $44K | Hold |
304
| – | – | ﹤0.01% | 1560 |
|
|
2016
Q1 | $31K | Hold |
304
| – | – | ﹤0.01% | 1720 |
|
|
2015
Q4 | $51K | Buy |
304
+117
| +63% | +$18K | ﹤0.01% | 1438 |
|
|
2015
Q3 | $26K | Buy |
187
+140
| +298% | +$31.4K | ﹤0.01% | 1415 |
|
|
2015
Q2 | $11K | Hold |
47
| – | – | ﹤0.01% | 1327 |
|
|
2015
Q1 | $8K | Buy |
+47
| New | +$7.63K | ﹤0.01% | 1517 |
|
Other funds holding NVAX
SCM
S
Zurich Cantonal Bank's NVAX Position: Q2 2026 in Review
Zurich Cantonal Bank held its Novavax (NVAX) position steady in Q2 2026 at 47,980 shares worth $452K. The position accounts for ﹤0.01% of the portfolio, ranked #1999.
Zurich Cantonal Bank first reported a position in NVAX in Q1 2015 and has held it in 43 quarters since. The position peaked at $4.46M in Q3 2021. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.
- Zurich Cantonal Bank held 47,980 shares of Novavax worth $452K as of Q2 2026.
- Zurich Cantonal Bank left its Novavax share count unchanged in Q2 2026.
- Novavax made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1999 holding.
- Zurich Cantonal Bank first reported a position in Novavax in Q1 2015 and has held it in 43 quarters since.
- Zurich Cantonal Bank's Novavax position peaked at $4.46M in Q3 2021.
- 266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.
Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.